Kardigan, Inc. announced the completion of patient enrollment in its Phase 2b KATALYST-AV clinical trial evaluating ataciguat for patients with aortic stenosis. The company also disclosed that the primary endpoint assessment of aortic valve calcium will be conducted at Week 48, alongside an internal interim analysis at Week 24. Topline data from this trial is expected in the second half of 2027. Kardigan operates as a clinical-stage precision cardiovascular company developing medicines targeting specific cardiovascular diseases.
